CRL
Charles River Laboratories International, Inc. Health Care Services-Commercial Physical & Biological Research S&P 500Russell 3000
$359.41Close
$17.7BMarket cap
$149.93 – $376.1052-week range
Nov 4, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Near its high 4% below its 52-week high
Cautions
- Extended 4.8 ATR above its 50-day average
- Earnings shrinking EPS −103% year on year
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 4.1%
price change
1mo
up 21.8%
price change
12-month return
up 101%
market up 11% ·
its own up 89%
F-score
—
— Not assessed
Altman Z″
1.81
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.6×
price / book
Earnings yield
up 0.1%
EBIT / enterprise value
Cheaper than
34%
of the market · expensive
Revenue growth
down 1%
year on year
EPS growth
down 103%
latest quarter · +58 pts
Sales growth
down 3%
latest quarter · -4 pts
ROE
down 4%
return on equity
Free cash margin
up 13%
$518.5M FCF
D/E
0.68
long-term debt / equity
Net debt / EBITDA
4.5×
Interest cover
—EBIT / interest
Trade setup
ATR%
3.9%
$14.12 a day · 2×ATR $331.18
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
13.7%
by Nov 20, 2026 · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Heavily indebted Net debt is 4.5 times EBITDA — roughly 4 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Revenue shrinking Revenue fell 0.9% over the year, from $4.0B to $4.0B.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+14% vs market2 sessions after results
Options
$2.2M64.6% IV · activity
Financials
- Net -4%
- Free cash 13%
- Cash
- Long-term debt
| FY2020Dec 26, 2020 | FY2021Dec 25, 2021 | FY2022Dec 31, 2022 | FY2023Dec 30, 2023 | FY2024Dec 28, 2024 | FY2025Dec 27, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Operating income | $432.7M | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M |
| Net income | $364.3M | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
| Net margin | 12% | 11% | 12% | 11% | 1% | -4% |
| Earnings per share | $7.20 | $7.60 | $9.48 | $9.22 | $0.43 | -$2.91 |
| Free cash flow | $380.0M | $532.0M | $294.9M | $365.4M | $501.6M | $518.5M |
| Free cash margin | 13% | 15% | 7% | 9% | 12% | 13% |
| Cash | $228.4M | $241.2M | $233.9M | $276.8M | $194.6M | $213.8M |
| Long-term debt | $1.9B | $2.7B | $2.7B | $2.6B | $2.2B | $2.1B |
| Shareholders' equity | $2.1B | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Shares outstanding | 49.77m | 50.48m | 50.94m | 51.34m | 51.14m | 49.22m |
Next report
Nov 4, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±13.7%
$315 – $415 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±2.9%
last 4: +13.4% · -2.3% · +3.6% · -1.1%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
4.7× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 64.6% priced · 51.4% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $2.2M calls $1.8M · puts $429,200 · latest session
- 0.24× -0.24 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +909 · puts +819 past week
For options traders: ATM IV 64.6% (+6.4% 1w) · 1m ÷ 3m IV 1.21 · 25Δ skew 3.1 pts · Net GEX $2.2M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 27, 2026 | 39d |
| May 7, 2026 | Quarterly ↗ | Mar 28, 2026 | 40d |
| Feb 18, 2026 | Annual ↗ | Dec 27, 2025 | 53d |
| Nov 5, 2025 | Quarterly ↗ | Sep 27, 2025 | 39d |
| Aug 6, 2025 | Quarterly ↗ | Jun 28, 2025 | 39d |
| May 7, 2025 | Quarterly ↗ | Mar 29, 2025 | 39d |
| Feb 19, 2025 | Annual ↗ | Dec 28, 2024 | 53d |
| Nov 6, 2024 | Quarterly ↗ | Sep 28, 2024 | 39d |
| Aug 7, 2024 | Quarterly ↗ | Jun 29, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 30, 2024 | 40d |
| Feb 14, 2024 | Annual ↗ | Dec 30, 2023 | 46d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 24, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| May 11, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 25, 2026 | Regulation FD ↗ |
| Feb 18, 2026 | Results ↗ |
| Feb 18, 2026 | Director or officer change ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Jan 9, 2026 | Director or officer change ↗ |
| Dec 3, 2025 | Regulation FD ↗ |
| Nov 17, 2025 | Other events ↗ |
| Nov 5, 2025 | Results ↗ |